Abcellera Biologics is trading 4.15% up at $11.05, broadly aligned with the Nasdaq Composite’s 0.69% gain rather than a newly announced company-specific catalyst.
- The company’s official news page shows no August 25 announcement.
- Latest listed developments are August 12 public-offering pricing and August 10 positive ABCL635 Phase 2 results.
- The move follows a 6.27% decline on August 24.